TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.~* Children, male or female, aged between 3 and 17 years at the time of the first study vaccination.~* Written informed consent obtained from the subject parent(s) or LAR(s) of the subject. Assent obtained from the subject when applicable.~* Healthy children as established by medical history and clinical examination when entering into the study.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Clinically or virologically confirmed influenza infection within six months preceding the study start.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* Previous administration of any H1N1 A/California-like vaccine.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.~* If the subject is female and if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.~* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.~* Known use of an analgesic or antipyretic medication within 12 hours prior to first vaccination.~* Child in Care.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects receiving alternative dose of GSK23440272A vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients included in this study are patients with RA (either newly or previously diagnosed) with their age between 18-50 years old having the same normal range of body mass index~Exclusion Criteria:~1. - The investigators will exclude patients with risk factors for atherosclerosis other than rheumatoid arthritis such as:~   * Smoking.~  * Obesity.~  * Hypertension.~  * Diabetes.~  * History of renal or liver diseases.~  * Corticosteroid therapy. 2- Intercurrent infections as they may interfere with levels of metalloproteinases.~     3- Pregnant or lactating females .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- RA patients treated with methotrexate (Type: ACTIVE_COMPARATOR): Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound.
- RA patients treated with methotrexate plus doxycycline (Type: ACTIVE_COMPARATOR): Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal, non-pregnant, non-lactating women age 18-40 years old~* Body Mass Index (BMI) ≥18 kg/m² and \<30 kg/m²~* Regular spontaneous menstrual cycle~* Others as dictated by FDA-approved protocol~Exclusion Criteria:~* Any condition which contraindicates the use of combination oral contraceptives~* Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening~* Thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders; thrombogenetic valvulopathies or rhythm disorders~* Others as dictated by FDA-approved protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Treatment I: (DR-102) (Type: EXPERIMENTAL): 21 days of combination active pills (containing 150 mcg desogestrel \[DSG\]/20 mcg ethinyl estradiol \[EE\]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
- Treatment II (Type: ACTIVE_COMPARATOR): 21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary hypercholesterolemia or mixed dyslipidemia~2. Subject meeting All of the following diagnoses at Baseline visit:~   * TG≦350 mg/dL~  * ALT and AST≦ 2.5 times of upper limit of normal (ULN) with no acute liver disease~  * Creatine kinase (CK) concentration≦2 times of UL N~  * Creatinine≦1.5 mg/dL~3. Subject who is willing and able to provide inform ed consent~Exclusion Criteria:~1. Female who is or intends to be pregnant or breast feeding, or has childbearing potential but without effective contraception.~2. Subject with documented HIV~3. Subject with uncontrolled hypothyroidism according to the investigator's judgment~4. Subject with unstable cardiovascular disease (CVD), including but not limited to congestive heart failure (CHF) defined as New York Heart Association class III or IV, unstable angina, unstable arrhythmia according to the investigator's judgment~5. Subject with unstable hepatic or biliary disorders, including but not limited to acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer, jaundice , and chronic hepatitis B or C under antiviral therapy~6. Subject with the following medical histories:~   * History of malignancy, exceptions made for the following malignancies: a)those determined to be cured or in remission for ≥ 5 years, b) curatively resected basal cell or squamous cell skin cancers, c) cervical cancer in situ, or resected colonic polyps~  * Acute coronary syndrome with or without cardiac catheterization within the past 9 months~  * Therapeutic cardiac catheterization (due to reasons other than acute coronary syndrome) within the past 6 months~7. Any unstable comorbidities or clinical conditions , including laboratory abnormalities which could lead to unacceptable risk to subject or confound data interpretation , per investigatiors judgment~8. Use any lipid lowering agent within 6 weeks prior to initiating the study treatment ( recheck this criterion at Day 1)~9. Use cyclosporine within 6 weeks prior to initiating the study treatment (recheck this criterion at Day 1)~10. Use any investigational product within 6 weeks prior to initiating the study treatment ( recheck this criterion at Day 1)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pitavastatin (Type: ACTIVE_COMPARATOR): Pitavastatin
- Ezetimibe (Type: ACTIVE_COMPARATOR): Ezetimibe
- 1PC111 (Type: EXPERIMENTAL): 1PC111

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks prior to first visit~* Both genders; females of child bearing potential must be willing to use appropriate contraception~* Pre-bronchodilator FEV1 of 40-90% predicted~* Reversibility FEV1 of at least 12% and 200mLs~* Current asthma therapy that includes inhaled corticosteroid for at least 4 weeks prior to first visit~Exclusion Criteria:~* History of life threatening asthma~* Respiratory infection or candidiasis~* Asthma exacerbation requiring OCS within last 4 weeks or overnight hospital stay within the last 3 months~* Concurrent respiratory disease or other disease that would confound study participation of affect subject safety~* Allergies to study drugs, study drug excipients, medications related to study drugs~* Taking another investigational medication or medication prohibited for use during the study~* Previous treatment with FF or FF/VI in a phase II or III study~* Night shift workers~* Children in care

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- FF 100mcg once daily (Type: EXPERIMENTAL): Inhaled corticosteroid (ICS)
- FF 200mcg once daily (Type: EXPERIMENTAL): Inhaled corticosteroid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, between 18 and 80 years of age~* Ability to take pills~* Agreement to a regional with general anesthesia technique~Exclusion Criteria:~* Allergy to amide local anesthetics~* Presence of a progressive neurological deficit~* pre-existing coagulopathy~* Current infection~* Significant pulmonary disease contraindicating phrenic nerve blockade~* Chronic use of an opioid analgesic (\>3 months of a combined total of more than 40mg oxycodone equivalents a day)~* Inability to obtain ultrasound images of anatomy due to obesity.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Interscalene Block plus Sham Block (Type: SHAM_COMPARATOR): Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block.
- Interscalene plus PECS Blocks (Type: ACTIVE_COMPARATOR): Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 7 and 15 years~* Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria~* Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc.~Exclusion Criteria:~* Patients with vasomotor rhinitis or eosinophilic rhinitis~* Patients who have concurrent nasal disease that may affect the efficacy of TAU-284~* Patients with a history of any of the nasal surgical procedures~* Patients who have a positive result for pollen antigens which are dispersed during the study period~* Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats.~* Patients with current or previous history of drug allergy~* Patients who concurrently have renal function abnormalities that may cause safety problems etc.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- TAU-284 (Type: EXPERIMENTAL): Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Service Development: Assessing Non-attendance Rates in Outpatient Clinics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with appointments booked for 2 respiratory outpatient clinics~Exclusion criteria~Patients likely to only need one appointment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- control group (Type: NO_INTERVENTION): This group received usual care and did not receive a telephone reminder
- telephone reminder group (Type: ACTIVE_COMPARATOR): This group received a telephone reminder for their clinic appointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy, male and non-pregnant female subjects, 18 years of age or older.~2. A diagnosis of papulopustular rosacea with ≥30 inflammatory facial lesions at Baseline. Subjects must have no more than 2 nodular lesions, at Baseline.~3. Subjects with the presence of telangiectasia at Baseline.~4. Subjects with an erythema score of at least 2 on the Investigator Assessment of Erythema scale at Baseline.~5. Subjects with severe rosacea on the Investigators Global Assessment scale at Baseline.~Exclusion Criteria:~1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).~2. Subjects with nodular rosacea.~3. Standard exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): CLS001 (Omiganan) gel applied once daily
- Vehicle Gel (Type: PLACEBO_COMPARATOR): Vehicle gel applied once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Quality of Decisions About Treatment of Menopausal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged 40-60~* Talked with health care provider about ways to manage menopause within last year OR seriously considered taking medicine or supplement to manage menopause within the last year~Exclusion Criteria:~* Prior diagnosis of breast cancer~* Surgical or medically induced menopause (ovaries removed)

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Group not receiving the decision aid (DVD and booklet)
- Decision Aid (Type: EXPERIMENTAL): Group receiving the decision aid (DVD/booklet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment~* Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.~* Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment~Exclusion Criteria:~* Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation~* History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation~* History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation~* Clinical evidence of prostate cancer at initiation~* Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation~* History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study~* History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation)~* Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 2.5 mg Tadalafil (Type: EXPERIMENTAL): None
- 5.0 mg Tadalafil (Type: EXPERIMENTAL): None
- 0.2 mg Tamsulosin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete